


## PKG drug G1

<b>Cat. No.:</b>	HY-112197		
<b>CAS No.:</b>	374703-78-3		
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>11</sub> N <sub>3</sub> OS		
<b>Molecular Weight:</b>	257.31		
<b>Target:</b>	PKG		
<b>Pathway:</b>	Stem Cell/Wnt		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 75 mg/mL (291.48 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.8864 mL	19.4318 mL	38.8636 mL
	5 mM	0.7773 mL	3.8864 mL	7.7727 mL
	10 mM	0.3886 mL	1.9432 mL	3.8864 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

PKG agent G1 targets C42 of PKG I $\alpha$ . PKG agent G1 can couple to vasodilation and blood pressure lowering by a C42 PKG I $\alpha$ -independent mechanism.

#### IC<sub>50</sub> & Target

PKG I $\alpha$ <sup>[1]</sup>

#### In Vivo

PKG drug G1 induces vasodilation of isolated resistance blood vessels and blood pressure lowering in a mouse model of angiotensin II-induced hypertension. PKG drug G1 efficiently relaxes WT but not knockin (KI) vessels, which is then assessed in a murine model of hypertension. PKG drug G1 lowers blood pressure in hypertensive WT, but not KI, mice in vivo. PKG drug G1 is tested in vivo in healthy mice implanted with telemetric devices that allow blood pressure and heart rate to be constantly monitored. PKG drug G1 or vehicle control is administered by intraperitoneal injection, and the acute impact on hemodynamics assessed. PKG drug G1 administered at 7.4 mg/kg does not decrease blood pressure, but there is a concomitant reflex tachycardia. When this is repeated using 14.8 mg/kg dose of PKG drug G1, again blood pressure is not altered-but this higher dose induces a potentiated increase in heart rate<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## PROTOCOL

### Animal Administration <sup>[1]</sup>

Mice<sup>[1]</sup>

Mice constitutively expressing PKG  $\alpha$  Cys42Ser are generated on a pure C57BL/6 background. Age-matched and body weight-matched WT or PKG  $\alpha$  Cys42Ser KI male mice are used in all studies. Blood pressure and heart rate are assessed by radio telemetry in conscious freely moving mice. Alzet osmotic mini-pumps are used to deliver angiotensin II at 1.1 mg/kg per day in some studies. PKG drug G1 is delivered intraperitoneally (3.7-14.8 mg/kg) or orally (20 mg/kg) in some studies. To deliver PKG drug G1 orally, without stress or risk of dislodging the telemetric probe catheter, it is provided suspended in water and set in gelatin flavored with sodium saccharin<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Nat Commun. 2022 Aug 4;13(1):4537.
- Research Square Preprint. 2022 Jan.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Burgoyne JR, et al. Proof of Principle for a Novel Class of Antihypertensives That Target the Oxidative Activation of PKG  $\alpha$  (Protein Kinase G  $\alpha$ ). Hypertension. 2017 Sep;70(3):577-586.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA